DE69926522D1 - Gefriergetrockneter, attenuierter hepeatitis-a-lebendimpfstoff und seine stabilisatoren - Google Patents

Gefriergetrockneter, attenuierter hepeatitis-a-lebendimpfstoff und seine stabilisatoren

Info

Publication number
DE69926522D1
DE69926522D1 DE69926522T DE69926522T DE69926522D1 DE 69926522 D1 DE69926522 D1 DE 69926522D1 DE 69926522 T DE69926522 T DE 69926522T DE 69926522 T DE69926522 T DE 69926522T DE 69926522 D1 DE69926522 D1 DE 69926522D1
Authority
DE
Germany
Prior art keywords
live vaccine
attenuated
hepeatitis
stabilizers
freeze
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69926522T
Other languages
English (en)
Inventor
Jingye Liu
Pengfu Wang
Guangpu Li
Baosheng Xie
Zongming Song
Shuyan Li
Jing Liu
Ying Yu
Xizhen Zhang
Ben Liang
Lingjiu Liu
Wei Wang
Ling Zhang
Yong Xue
Jing Li
Yuhong Li
Hui Lin
Zongju Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Institute of Biological Products
Original Assignee
Changchun Institute of Biological Products
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Institute of Biological Products filed Critical Changchun Institute of Biological Products
Application granted granted Critical
Publication of DE69926522D1 publication Critical patent/DE69926522D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE69926522T 1998-10-19 1999-10-10 Gefriergetrockneter, attenuierter hepeatitis-a-lebendimpfstoff und seine stabilisatoren Expired - Lifetime DE69926522D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN98120633A CN1053590C (zh) 1998-10-19 1998-10-19 冻干甲型肝炎减毒活疫苗及其保护剂
PCT/CN1999/000157 WO2000023104A1 (fr) 1998-10-19 1999-10-10 Vaccin lyophilise a virus vivant modifie d'hepatite a et son stabilisant

Publications (1)

Publication Number Publication Date
DE69926522D1 true DE69926522D1 (de) 2005-09-08

Family

ID=5226823

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69926522T Expired - Lifetime DE69926522D1 (de) 1998-10-19 1999-10-10 Gefriergetrockneter, attenuierter hepeatitis-a-lebendimpfstoff und seine stabilisatoren

Country Status (8)

Country Link
US (1) US6884422B1 (de)
EP (1) EP1123710B1 (de)
KR (1) KR100702086B1 (de)
CN (1) CN1053590C (de)
AT (1) ATE300955T1 (de)
AU (1) AU6076299A (de)
DE (1) DE69926522D1 (de)
WO (1) WO2000023104A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1942932T3 (pl) 2005-08-08 2013-11-29 Univ Oregon Health & Science Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR063606A1 (es) * 2006-11-07 2009-02-04 Acambis Inc Estabilizacion de vacunas mediante liofilizacion
ES2621511T3 (es) 2007-04-06 2017-07-04 Takeda Vaccines, Inc. Métodos y composiciones para virus vivos atenuados
CN101537186B (zh) * 2009-04-30 2011-04-06 长春百克生物科技股份公司 一种不含明胶的疫苗冻干保护剂
CN102512686B (zh) * 2010-12-21 2013-07-24 成都生物制品研究所有限责任公司 一种疫苗保护剂、狂犬病疫苗及其制备方法
CN102512685B (zh) * 2010-12-21 2016-01-20 成都生物制品研究所有限责任公司 一种疫苗保护剂、麻疹乙型脑炎联合疫苗及其制备方法
CN102228687B (zh) * 2011-06-24 2012-10-10 浙江普康生物技术股份有限公司 不含明胶、人血白蛋白保护剂的冷冻干燥甲型肝炎减毒活疫苗及制备方法
US9283270B2 (en) 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
CN103893776B (zh) * 2014-03-18 2016-04-06 中国农业科学院兰州兽医研究所 羊传染性脓疱病毒细胞弱毒疫苗耐热冻干保护剂及其制备方法和应用
KR101648106B1 (ko) 2014-04-29 2016-08-17 대한민국 A형 간염 바이러스 항원 및 e형 간염 바이러스 항원 동시 생산방법 및 생산된 항원을 함유하는 간염 예방 백신 및 진단 키트
KR102494066B1 (ko) 2015-09-15 2023-01-31 주식회사 엘지생활건강 Ａ형 간염 예방 접종을 위한 용해성 미세바늘 패치
US20190275136A1 (en) * 2016-09-19 2019-09-12 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US20220125042A1 (en) * 2017-05-17 2022-04-28 Universidade Nova De Lisboa Cryoprotectant and/or cryopreservant composition, methods and uses thereof
US11738075B2 (en) 2018-03-20 2023-08-29 National Research Council Of Canada Method for lyophilizing live vaccine strains of Francisella tularensis
US11390853B2 (en) 2019-04-26 2022-07-19 Case Western Reserve University Freeze dried viral nanoparticle constructs
CN110101864A (zh) * 2019-05-31 2019-08-09 辽宁茂康源生物科技有限公司 一种无血清人用狂犬病疫苗的保护剂及其应用
CN110585439B (zh) * 2019-09-30 2023-06-09 长春生物制品研究所有限责任公司 一种改良型的冻干甲型肝炎减毒活疫苗稳定剂、疫苗半成品、疫苗成品及其制备方法
CN110669739A (zh) * 2019-09-30 2020-01-10 长春生物制品研究所有限责任公司 一种新型甲型肝炎病毒抗原制备方法
CN111000990A (zh) * 2019-12-19 2020-04-14 广东渔跃生物技术有限公司 一种鸭坦布苏病毒和鸭腺病毒二联灭活疫苗及其制备方法
CN112342318B (zh) * 2020-12-09 2023-05-30 陕西师范大学 一种用于检测新型冠状病毒SARS-CoV2的引物对、反应冻干管及试剂盒
CN113577262B (zh) * 2021-08-06 2022-04-19 湖北省农业科学院畜牧兽医研究所 一种耐热保护剂及其作为禽用冻干疫苗稀释液的应用与新城疫耐热活疫苗及其制备方法
CN113652404B (zh) * 2021-08-25 2024-03-26 江苏省农业科学院 一种猪圆环病毒的冻干保护剂及其在保藏中的应用
WO2024018452A1 (en) 2022-07-18 2024-01-25 Yeda Research And Development Co. Ltd. Albumin protein variants, production thereof and uses of same
CN116510025B (zh) * 2023-04-28 2024-02-13 长春祈健生物制品有限公司 提高水痘病毒疫苗滴度稳定性的冻干保护剂及制备方法
CN116421733B (zh) * 2023-06-08 2023-09-12 金宇保灵生物药品有限公司 可用于猪多杀性巴氏杆菌病活疫苗的疫苗耐热保护剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB799644A (en) * 1955-01-19 1958-08-13 Commonweath Scient And Ind Res Method for the dried storage of micro-organisms
US3557524A (en) * 1969-05-28 1971-01-26 John R Zimmerman Strip material folding and packaging machine
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPH0761955B2 (ja) * 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
FR2633518B1 (fr) * 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
DE69319728T2 (de) * 1992-05-23 1999-02-04 Smithkline Beecham Biolog Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
CA2144317C (en) * 1992-09-18 2004-08-03 Ann W. Funkhouser Hepatitis a virus vaccines
CN1029239C (zh) * 1992-12-29 1995-07-05 卫生部长春生物制品研究所 甲型肝炎疫苗的生产方法
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
EP1516628B1 (de) * 1995-07-27 2013-08-21 Genentech, Inc. Stabile isotonische lyophilisierte Proteinzusammensetzung
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
JP2000507963A (ja) * 1996-12-20 2000-06-27 メルク エンド カンパニー インコーポレーテッド 凍結乾燥ワクチン用安定剤
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法

Also Published As

Publication number Publication date
ATE300955T1 (de) 2005-08-15
KR100702086B1 (ko) 2007-04-02
EP1123710A4 (de) 2002-03-27
EP1123710B1 (de) 2005-08-03
AU6076299A (en) 2000-05-08
EP1123710A1 (de) 2001-08-16
CN1053590C (zh) 2000-06-21
WO2000023104A1 (fr) 2000-04-27
US6884422B1 (en) 2005-04-26
CN1214938A (zh) 1999-04-28
KR20010082233A (ko) 2001-08-29

Similar Documents

Publication Publication Date Title
DE69926522D1 (de) Gefriergetrockneter, attenuierter hepeatitis-a-lebendimpfstoff und seine stabilisatoren
EA200101167A1 (ru) Способ сохранения вирусов и микоплазмы
NO913558L (no) Fremgangsmaate ved fremstilling av xenogene antistoffer.
TR200002973T2 (tr) Isı şoku proteinlerini kullanarak enflamatuar hastalıkların tedavi edilmesi
ATE299712T1 (de) Stabilisatoren für lebendimpfstoffe
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
DE68929323T2 (de) Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
DK1030690T3 (da) Rekombinante vacciner, der omfatter immunogene svækkede bakterier med RpoS positiv fænotype
IL138306A0 (en) Polynucleotide composition, method of preparation and use thereof
ATE375804T1 (de) Ribavirin-enthaltende vakzine
ATE452230T1 (de) Waschbare und knitterfreie wollfasern mit dimensionalstabilität sowie herstellungsverfahren
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
DE68915359D1 (de) Verfahren zur Stabilisierung von Impfstoffen, Assoziationen von attenuierten, lyophilisierten Impfstoffen und erhaltene Zusammensetzungen.
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse
DE69801036T2 (de) Verfahren zur Wärmebehandlung von Holz
DE422566T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)-l-thiazolidin-4-carbonsaeure-derivaten.
DK180291D0 (da) Fremgangsmaade til varmebehandling af frisk maelk
DE69003629D1 (de) Vorbrennkammer mit waermedaemmung und verfahren fuer seine herstellung.
JP2005513086A5 (de)
KR880013575A (ko) 안정한 동결건조된 생체 헤르페스 바이러스 백신
ATE3058T1 (de) Herpes-virus-impfstoff und seine herstellung.
AR024212A1 (es) Virus celo recombinante y adn de virus celo.
DE69228112T2 (de) Verfahren zur verbesserung des gedächtnisses und zur steigerung der lebensqualitet
Gattullo et al. The metabolic effects of gaboon viper(Bitis gabonica) venom in the anaesthetised rabbit.
ATE159758T1 (de) Azelluläre impfstoffe

Legal Events

Date Code Title Description
8332 No legal effect for de